News – Page 1146 – Endpoints News

Hot on the heels of a clinical hold, Arrowhead torches its clinical pipeline, slashes staff

9 years ago

Another Humira copycat comes through in PhIII; Tetra Discovery adds $10M for Alzheimer’s drug development

9 years ago

Step aside AstraZeneca, Pfizer/Merck KGaA jump ahead, getting a speedy review for their checkpoint rival avelumab

9 years ago

Stubborn Actelion CEO Clozel spurs shift in buyout talks, but J&J counters with a raised bid -- reports

9 years ago

AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro

9 years ago

Nivalis shares in meltdown as cystic fibrosis promise withers in PhII flop

9 years ago

Innovent Biologics sets a biotech record in China with $260M raise for PhIII work

9 years ago

Amicus maps out a 3-year delay at the FDA for lead drug, sending shares into a tailspin

9 years ago

House lines up biotech lollipops as support grows for an epic 21st Century Cures Act

9 years ago

Juno and the FDA screwed up. People died. What now?

9 years ago

Tired of being dumped by pharma partners, Vanderbilt’s neuroscience team takes a bold aim at the clinic

9 years ago

China backers help bankroll a $100M mega-round as an influential antibody engineer readies trials

9 years ago

Porges sees the pros — and cons — for Biogen in Lilly’s Alzheimer’s snafu; Idera forges development pact; UK ...

9 years ago

Will J&J come up with a big enough treasure trove to win an Actelion buyout?

9 years ago

The 10 most popular reports in Endpoints News — so far

9 years ago

Pfizer blueprints $200M R&D campus; Galapagos bags $50M milestone from Gilead

9 years ago

Two more patients die as Juno’s lead CAR-T turns lethal again; trial halted

9 years ago

GSK targets a new indication for Nucala, flags PhIII success for a rare disease

9 years ago

It’s over: Eli Lilly shares tank after its huge gamble on Alzheimer’s drug solanezumab ends in failure

9 years ago

Novartis’ recently departed oncology R&D chief is headed back to Dana-Farber and a new job in cancer research

9 years ago

Ex-Allergan prez Ingram forges $1B deal to sell Alzheimer’s biotech to Brent Saunders and the new crew at Allergan

9 years ago

Biogen vet Adam Koppel is raising cash for a new life sciences fund at Bain Capital

9 years ago

Fate raises $57M; Biogen vet named CSO at Scholar Rock

9 years ago

Thinking bigger, Arch Venture closes in on $550M-plus biotech fund

9 years ago

First page Previous page 1143 1144 114511461147 1148 1149 Next page Last page